{"id":26772,"date":"2023-03-14T14:57:12","date_gmt":"2023-03-14T14:57:12","guid":{"rendered":"https:\/\/www.curiumpharma.com\/2023\/03\/14\/no-foreseeable-supply-challenges\/"},"modified":"2023-03-14T15:48:09","modified_gmt":"2023-03-14T15:48:09","slug":"no-foreseeable-supply-challenges","status":"publish","type":"post","link":"https:\/\/www.curiumpharma.com\/nl\/2023\/03\/14\/no-foreseeable-supply-challenges\/","title":{"rendered":"Curium confirms no supply challenges in North America and Europe for its ECLIPSE Phase 3 clinical trial"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"","protected":false},"author":89,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[91],"tags":[117,105,106],"class_list":["post-26772","post","type-post","status-publish","format-standard","hentry","category-persberichten","tag-news-nl","tag-nuclear-medicine-nl","tag-prl-nl"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Curium confirms no supply challenges in North America and Europe for its ECLIPSE Phase 3 clinical trial - Curium Pharma<\/title>\n<meta name=\"description\" content=\"Curium confirmed that the company has no foreseeable supply challenges of 177Lu-PSMA-I&amp;T for the company\u2019s ECLIPSE Phase 3 clinical trial.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.curiumpharma.com\/nl\/2023\/03\/14\/no-foreseeable-supply-challenges\/\" \/>\n<meta property=\"og:locale\" content=\"nl_NL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Curium confirms no supply challenges in North America and Europe for its ECLIPSE Phase 3 clinical trial - Curium Pharma\" \/>\n<meta property=\"og:description\" content=\"Curium confirmed that the company has no foreseeable supply challenges of 177Lu-PSMA-I&amp;T for the company\u2019s ECLIPSE Phase 3 clinical trial.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.curiumpharma.com\/nl\/2023\/03\/14\/no-foreseeable-supply-challenges\/\" \/>\n<meta property=\"og:site_name\" content=\"Curium Pharma\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-14T14:57:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-14T15:48:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.curiumpharma.com\/wp-content\/uploads\/2018\/05\/Curium-Logo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"818\" \/>\n\t<meta property=\"og:image:height\" content=\"523\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Elisabeth Baucells\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/www.curiumpharma.com\/wp-content\/uploads\/2019\/04\/Curium-Logo-01-with-transparent-bckgrnd-w-tagline-1.png\" \/>\n<meta name=\"twitter:label1\" content=\"Geschreven door\" \/>\n\t<meta name=\"twitter:data1\" content=\"Elisabeth Baucells\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.curiumpharma.com\\\/nl\\\/2023\\\/03\\\/14\\\/no-foreseeable-supply-challenges\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.curiumpharma.com\\\/nl\\\/2023\\\/03\\\/14\\\/no-foreseeable-supply-challenges\\\/\"},\"author\":{\"name\":\"Elisabeth Baucells\",\"@id\":\"https:\\\/\\\/www.curiumpharma.com\\\/#\\\/schema\\\/person\\\/e4f8faf9cb0b0abf9a175f21afe353c6\"},\"headline\":\"Curium confirms no supply challenges in North America and Europe for its ECLIPSE Phase 3 clinical trial\",\"datePublished\":\"2023-03-14T14:57:12+00:00\",\"dateModified\":\"2023-03-14T15:48:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.curiumpharma.com\\\/nl\\\/2023\\\/03\\\/14\\\/no-foreseeable-supply-challenges\\\/\"},\"wordCount\":16,\"keywords\":[\"news\",\"Nuclear medicine\",\"PRL\"],\"articleSection\":[\"Persberichten\"],\"inLanguage\":\"nl-NL\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.curiumpharma.com\\\/nl\\\/2023\\\/03\\\/14\\\/no-foreseeable-supply-challenges\\\/\",\"url\":\"https:\\\/\\\/www.curiumpharma.com\\\/nl\\\/2023\\\/03\\\/14\\\/no-foreseeable-supply-challenges\\\/\",\"name\":\"Curium confirms no supply challenges in North America and Europe for its ECLIPSE Phase 3 clinical trial - Curium Pharma\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.curiumpharma.com\\\/#website\"},\"datePublished\":\"2023-03-14T14:57:12+00:00\",\"dateModified\":\"2023-03-14T15:48:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.curiumpharma.com\\\/#\\\/schema\\\/person\\\/e4f8faf9cb0b0abf9a175f21afe353c6\"},\"description\":\"Curium confirmed that the company has no foreseeable supply challenges of 177Lu-PSMA-I&T for the company\u2019s ECLIPSE Phase 3 clinical trial.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.curiumpharma.com\\\/nl\\\/2023\\\/03\\\/14\\\/no-foreseeable-supply-challenges\\\/#breadcrumb\"},\"inLanguage\":\"nl-NL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.curiumpharma.com\\\/nl\\\/2023\\\/03\\\/14\\\/no-foreseeable-supply-challenges\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.curiumpharma.com\\\/nl\\\/2023\\\/03\\\/14\\\/no-foreseeable-supply-challenges\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.curiumpharma.com\\\/nl\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Curium confirms no supply challenges in North America and Europe for its ECLIPSE Phase 3 clinical trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.curiumpharma.com\\\/#website\",\"url\":\"https:\\\/\\\/www.curiumpharma.com\\\/\",\"name\":\"Curium Pharma\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.curiumpharma.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"nl-NL\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.curiumpharma.com\\\/#\\\/schema\\\/person\\\/e4f8faf9cb0b0abf9a175f21afe353c6\",\"name\":\"Elisabeth Baucells\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/33b8a272bd481f1f7e7f35ba80eadfdcbbc3bd405b0dce428b88ffe41082b8c7?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/33b8a272bd481f1f7e7f35ba80eadfdcbbc3bd405b0dce428b88ffe41082b8c7?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/33b8a272bd481f1f7e7f35ba80eadfdcbbc3bd405b0dce428b88ffe41082b8c7?s=96&d=mm&r=g\",\"caption\":\"Elisabeth Baucells\"},\"url\":\"https:\\\/\\\/www.curiumpharma.com\\\/nl\\\/author\\\/elisabeth-baucellscuriumpharma-com\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Curium confirms no supply challenges in North America and Europe for its ECLIPSE Phase 3 clinical trial - Curium Pharma","description":"Curium confirmed that the company has no foreseeable supply challenges of 177Lu-PSMA-I&T for the company\u2019s ECLIPSE Phase 3 clinical trial.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.curiumpharma.com\/nl\/2023\/03\/14\/no-foreseeable-supply-challenges\/","og_locale":"nl_NL","og_type":"article","og_title":"Curium confirms no supply challenges in North America and Europe for its ECLIPSE Phase 3 clinical trial - Curium Pharma","og_description":"Curium confirmed that the company has no foreseeable supply challenges of 177Lu-PSMA-I&T for the company\u2019s ECLIPSE Phase 3 clinical trial.","og_url":"https:\/\/www.curiumpharma.com\/nl\/2023\/03\/14\/no-foreseeable-supply-challenges\/","og_site_name":"Curium Pharma","article_published_time":"2023-03-14T14:57:12+00:00","article_modified_time":"2023-03-14T15:48:09+00:00","og_image":[{"width":818,"height":523,"url":"https:\/\/www.curiumpharma.com\/wp-content\/uploads\/2018\/05\/Curium-Logo.jpg","type":"image\/jpeg"}],"author":"Elisabeth Baucells","twitter_card":"summary_large_image","twitter_image":"https:\/\/www.curiumpharma.com\/wp-content\/uploads\/2019\/04\/Curium-Logo-01-with-transparent-bckgrnd-w-tagline-1.png","twitter_misc":{"Geschreven door":"Elisabeth Baucells"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.curiumpharma.com\/nl\/2023\/03\/14\/no-foreseeable-supply-challenges\/#article","isPartOf":{"@id":"https:\/\/www.curiumpharma.com\/nl\/2023\/03\/14\/no-foreseeable-supply-challenges\/"},"author":{"name":"Elisabeth Baucells","@id":"https:\/\/www.curiumpharma.com\/#\/schema\/person\/e4f8faf9cb0b0abf9a175f21afe353c6"},"headline":"Curium confirms no supply challenges in North America and Europe for its ECLIPSE Phase 3 clinical trial","datePublished":"2023-03-14T14:57:12+00:00","dateModified":"2023-03-14T15:48:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.curiumpharma.com\/nl\/2023\/03\/14\/no-foreseeable-supply-challenges\/"},"wordCount":16,"keywords":["news","Nuclear medicine","PRL"],"articleSection":["Persberichten"],"inLanguage":"nl-NL"},{"@type":"WebPage","@id":"https:\/\/www.curiumpharma.com\/nl\/2023\/03\/14\/no-foreseeable-supply-challenges\/","url":"https:\/\/www.curiumpharma.com\/nl\/2023\/03\/14\/no-foreseeable-supply-challenges\/","name":"Curium confirms no supply challenges in North America and Europe for its ECLIPSE Phase 3 clinical trial - Curium Pharma","isPartOf":{"@id":"https:\/\/www.curiumpharma.com\/#website"},"datePublished":"2023-03-14T14:57:12+00:00","dateModified":"2023-03-14T15:48:09+00:00","author":{"@id":"https:\/\/www.curiumpharma.com\/#\/schema\/person\/e4f8faf9cb0b0abf9a175f21afe353c6"},"description":"Curium confirmed that the company has no foreseeable supply challenges of 177Lu-PSMA-I&T for the company\u2019s ECLIPSE Phase 3 clinical trial.","breadcrumb":{"@id":"https:\/\/www.curiumpharma.com\/nl\/2023\/03\/14\/no-foreseeable-supply-challenges\/#breadcrumb"},"inLanguage":"nl-NL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.curiumpharma.com\/nl\/2023\/03\/14\/no-foreseeable-supply-challenges\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.curiumpharma.com\/nl\/2023\/03\/14\/no-foreseeable-supply-challenges\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.curiumpharma.com\/nl\/"},{"@type":"ListItem","position":2,"name":"Curium confirms no supply challenges in North America and Europe for its ECLIPSE Phase 3 clinical trial"}]},{"@type":"WebSite","@id":"https:\/\/www.curiumpharma.com\/#website","url":"https:\/\/www.curiumpharma.com\/","name":"Curium Pharma","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.curiumpharma.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"nl-NL"},{"@type":"Person","@id":"https:\/\/www.curiumpharma.com\/#\/schema\/person\/e4f8faf9cb0b0abf9a175f21afe353c6","name":"Elisabeth Baucells","image":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/secure.gravatar.com\/avatar\/33b8a272bd481f1f7e7f35ba80eadfdcbbc3bd405b0dce428b88ffe41082b8c7?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/33b8a272bd481f1f7e7f35ba80eadfdcbbc3bd405b0dce428b88ffe41082b8c7?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/33b8a272bd481f1f7e7f35ba80eadfdcbbc3bd405b0dce428b88ffe41082b8c7?s=96&d=mm&r=g","caption":"Elisabeth Baucells"},"url":"https:\/\/www.curiumpharma.com\/nl\/author\/elisabeth-baucellscuriumpharma-com\/"}]}},"_links":{"self":[{"href":"https:\/\/www.curiumpharma.com\/nl\/wp-json\/wp\/v2\/posts\/26772","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.curiumpharma.com\/nl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.curiumpharma.com\/nl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.curiumpharma.com\/nl\/wp-json\/wp\/v2\/users\/89"}],"replies":[{"embeddable":true,"href":"https:\/\/www.curiumpharma.com\/nl\/wp-json\/wp\/v2\/comments?post=26772"}],"version-history":[{"count":0,"href":"https:\/\/www.curiumpharma.com\/nl\/wp-json\/wp\/v2\/posts\/26772\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.curiumpharma.com\/nl\/wp-json\/wp\/v2\/media?parent=26772"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.curiumpharma.com\/nl\/wp-json\/wp\/v2\/categories?post=26772"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.curiumpharma.com\/nl\/wp-json\/wp\/v2\/tags?post=26772"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}